Abstract: The present invention relates to a method for pesticide detection in a sample, based on the use of particular CYP450 enzymes, CYP2B11 and CYP2B10. Furthermore, the present invention relates to a kit comprising these CYP450 enzymes, and related uses in pesticide detection, including simultaneous pesticide detection.

Abstract: Disclosed are infant formulas comprising at least about 6.5 g/L, on an as-fed basis, of an enriched whey protein concentrate, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. The formulas also typically include at least about 5 mg/L of gangliosides, at least about 150 mg/L of phospholipids, and at least about 70 mg/L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, all of which are provided in whole or in part from the enriched whey protein concentrate. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

Abstract: Disclosed are infant formulas comprising, on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. From about 50% to 100% by weight of each of the gangliosides, phospholipids, lactoferrin, and sialic acid is provided by an enriched whey protein concentrate, with the concentrate representing at least about 6.5 g/L of the formula on an as-fed basis. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

Abstract: Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis (A) at least about 5 mg/L of gangliosides, (B) at least about 150 mg/L of phospholipids, and (C) lactoferrin, and (D) at least about 70 mg/L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

Abstract: Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis, at least about 5 mg/L of gangliosides, at least about 150 mg/L of phospholipids, at least about 70 mg/L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

Abstract: Disclosed are nutritional compositions for treating rheumatic diseases. The nutritional compositions contain a fat source containing at least one of: 1) at least one omega-3 long chain polyunsaturated fatty acid and 2) at least one omega-6 long chain polyunsaturated fatty acid; a carbohydrate source; a protein source; and at least one of a Boswellia extract and a Phlebodium extract. Also disclosed are methods of treating rheumatic diseases and symptoms thereof, involving administering to a subject an effective amount of the aforementioned nutritional composition.